Kyverna Therapeutics Inc. (KYTX)
2.13
0.15 (7.58%)
At close: Apr 02, 2025, 3:59 PM
7.58% (1D)
| Bid | 1.9 |
| Market Cap | 92.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.33 |
| PE Ratio (ttm) | -0.64 |
| Forward PE | -0.98 |
| Analyst | Buy |
| Ask | 2.19 |
| Volume | 238,627 |
| Avg. Volume (20D) | 356,003 |
| Open | 1.99 |
| Previous Close | 1.98 |
| Day's Range | 1.94 - 2.16 |
| 52-Week Range | 1.88 - 24.91 |
| Beta | 2.58 |
About KYTX
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2024
Employees 112
Stock Exchange NASDAQ
Ticker Symbol KYTX
Website https://kyvernatx.com
Analyst Forecast
According to 5 analyst ratings, the average rating for KYTX stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 838.97% from the latest price.
Stock Forecasts8 months ago
+1.23%
Kyverna Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
9 months ago
Kyverna Therapeutics shares are trading higher after the company announced KYV-101 received FDA IND clearance for the treatment of patients with treatment-refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 trial.
